1. Home
  2. NEPH vs NRXP Comparison

NEPH vs NRXP Comparison

Compare NEPH & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nephros Inc.

NEPH

Nephros Inc.

HOLD

Current Price

$4.49

Market Cap

60.0M

Sector

Health Care

ML Signal

HOLD

Logo NRX Pharmaceuticals Inc.

NRXP

NRX Pharmaceuticals Inc.

HOLD

Current Price

$2.28

Market Cap

70.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NEPH
NRXP
Founded
1997
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
60.0M
70.8M
IPO Year
2004
N/A

Fundamental Metrics

Financial Performance
Metric
NEPH
NRXP
Price
$4.49
$2.28
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
6
Target Price
$6.00
$30.67
AVG Volume (30 Days)
49.3K
1.7M
Earning Date
11-06-2025
11-17-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.14
N/A
Revenue
$17,930,000.00
$242,000.00
Revenue This Year
$33.32
N/A
Revenue Next Year
$12.27
$847.91
P/E Ratio
$31.54
N/A
Revenue Growth
32.36
N/A
52 Week Low
$1.39
$1.58
52 Week High
$6.42
$5.01

Technical Indicators

Market Signals
Indicator
NEPH
NRXP
Relative Strength Index (RSI) 40.89 46.84
Support Level $4.18 $2.00
Resistance Level $5.46 $2.48
Average True Range (ATR) 0.30 0.17
MACD -0.06 -0.02
Stochastic Oscillator 17.19 35.95

Price Performance

Historical Comparison
NEPH
NRXP

About NEPH Nephros Inc.

Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.

About NRXP NRX Pharmaceuticals Inc.

NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.

Share on Social Networks: